-:: Preclinical Studies Home ::-

> Home > Preclinical Studies > Clinical Program > QC Technology > Corporate Overview > Newsroom




»	Preclinical Studies Home
---------------------------
»	PHY906
	Colorectal Cancer
	Liver Cancer
	Pancreatic Cancer
	Scientific Abstracts
»	PHY626, PHY808, PHY777
------------------------------
»	Traditional Chinese Medicine
------------------------------

Preclinical Studies

Cancer is the second overall cause of death in the U.S. and many unmet needs exist within the field. Side effects from chemotherapy treatment are prevalent and such toxicities not only can prevent a patient from receiving the most effective chemotherapeutic dose, they can also adversely impact a patient’s quality-of-life. Additionally, in areas such as primary liver cancer, standard chemotherapeutic regimens do not exist. In other areas such as pancreatic cancer, standard regimens exhibit low response rates.

PhytoCeutica’s research and development efforts are focused on seeking solutions to these unmet needs. PhytoCeutica believes that traditional Chinese medicines (TCM), containing up to thousands of phytochemicals that synergistically act upon multiple targets and biological pathways, represent the next stage in oncology therapeutics. These botanical drugs, to be developed as FDA-approved prescription medicines, can be administered alone or in combination with current chemotherapies and will meet rigorous preclinical, clinical, and quality-control standards.

PHY906

PhytoCeutica’s leading patented drug candidate. It has been shown in preclinical studies to have the dual effect of reducing the toxic effects of chemotherapy as well as potentiating that chemotherapy’s antitumor effect.

PhytoCeutica is also evaluating three other pipeline products: PHY626, PHY808, and PHY777

I I I

PhytoCeutica, Inc. 5 Science Park, Suite 13,New Haven, CT 06511, Phone: 203-777-3462, Fax: 203-777-3538

E-mail: info@phytoceutica.com

www.audinwebdesign.com